Celldex Therapeutics, Inc.
NASDAQ: CLDX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Anthony S. Marucci
- Employees
- 186
- Headquarters
- Hampton, United States
- IPO year
- 1986
- Market cap
- $2.2B
- Website
- https://www.celldex.com
Loading CLDX…
Loading profile data…Frequently asked questions about CLDX
What does Celldex Therapeutics, Inc. (CLDX) do?
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a...
Where does CLDX trade?
Celldex Therapeutics, Inc. (CLDX) trades on the NASDAQ Capital Market.
What sector is CLDX in?
Celldex Therapeutics, Inc. (CLDX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Celldex Therapeutics, Inc.?
Anthony S. Marucci is the chief executive officer of Celldex Therapeutics, Inc. (CLDX).
Where is Celldex Therapeutics, Inc. headquartered?
Celldex Therapeutics, Inc. is headquartered in United States.
Does CLDX pay a dividend?
Celldex Therapeutics, Inc. (CLDX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLDX go public?
Celldex Therapeutics, Inc. (CLDX) completed its initial public offering in 1986.